S&P Futures
6,016.00 +29.00 (+0.48%) Dow Futures
44,671.00 +276.00 (+0.62%) Nasdaq Futures
20,966.00 +116.25 (+0.56%) Russell 2000 Futures
2,434.30 +20.70 (+0.86%) Crude Oil
71.13 -0.11 (-0.15%) Gold
2,683.40 -28.80 (-1.06%)
Eterna Therapeutics Inc. (ERNA)
After hours:
| Previous Close | 0.5322 |
| Open | 0.5791 |
| Bid | 0.4999 x 100 |
| Ask | 0.5706 x 100 |
| Day's Range | 0.5200 - 0.6000 |
| 52 Week Range | 0.5200 - 2.6300 |
| Volume | |
| Avg. Volume | 71,212 |
| Market Cap | 26.715M |
| Beta (5Y Monthly) | 7.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.3100 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireEterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market. Eterna received formal confirmation on November 12th, 2024 from Nasdaq’s Office of General Counsel, verifying that Eterna has met the market value of listed securities standard of at least $35 million, outlined in Listing Rule 5
- GlobeNewswire
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) today announced the successful completion of a comprehensive financial restructuring of the Company with the aim to accelerate its developmental activities and long-term success. This restructuring includes reduction of its liabilities by discontinuing a longstanding lease, reducing the debt on its balance sheet and a new round of financing through a private investment in publi
